pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Oncology · news · pharmadog
← back to Oncology
News · Oncology
909
stories
10d
FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issues
biospace
10d
STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more
stat
10d
Ex-Legend chief Ying Huang becomes CEO of K2, eyes $250M Series A
endpoints
11d
Silence causes uproar in rare blood cancer space as data sets high bar for competitors
biospace
11d
Vaderis gets $152M to run Phase 3 of rare bleeding disorder treatment
endpoints
11d
Vaderis hauls in $152M to test an AKT-targeting drug
biopharma dive
11d
IRBs have a problem. Can North Star’s nonprofit model save it?
stat
11d
STAT+: Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate?
stat
11d
Aura lays off 20% of workforce, rejigs C-suite amid R&D refocus on eye cancer
fiercebiotech
11d
STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
stat
11d
STAT+: FDA panel to weigh Grail’s Galleri test
stat
11d
Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline
biospace
11d
STAT+: Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial
stat
11d
BlossomHill, Latigo bloom on Nasdaq with oversubscribed IPOs
biospace
11d
STAT+: Heart failure drug from Tenax Therapeutics fails in pivotal study
stat
11d
Silence spells out Phase 2 success for gene-silencing drug in rare blood cancer
endpoints
11d
STAT+: Silence Therapeutics aims at Takeda with new data in rare blood cancer
stat
12d
ITM neuroendocrine tumor drug spurned by FDA over manufacturing qualms
fiercebiotech
12d
BioNTech vets get $25M seed funding for virtual cancer surveillance startup
endpoints
12d
Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug
fiercebiotech
12d
Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapies
fiercebiotech
12d
STAT+: The promise of radiopharmaceuticals smacks into safety concerns
stat
12d
Labcorp nabs FDA green light for BRAF melanoma diagnostic
fiercebiotech
12d
Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push
fiercebiotech
12d
From ex vivo to in vivo: Shaping the next generation of viral vector manufacturing
biospace
12d
Arpeggio plays final chord as biotech disbands on poor prospects for Nrf2 program
fiercebiotech
12d
Silence brings the noise to Takeda with phase 2 blood cancer win
fiercebiotech
14d
FDA to hold adcomm for Grail cancer test that failed in large, randomized trial
endpoints
14d
Replimune to ride wave of physician support to launch advanced melanoma therapy
biospace
14d
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
biopharma dive
← prev
page 5 of 31
next →
